Stay updated on Pembrolizumab & Endocrine Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Endocrine Therapy Clinical Trial page.
Latest updates to the Pembrolizumab & Endocrine Therapy Clinical Trial page
- Check5 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements in the latest release.SummaryDifference0.0%
- Check12 days agoChange DetectedNew interventions and treatments have been added to the study, including Fulvestrant, Letrozole, and Palbociclib, with detailed information on study locations and participant groups, while previous notices about delays in displaying study record information have been removed.SummaryDifference14%
- Check19 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the site has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference0.6%
- Check27 days agoChange DetectedThe website has posted a new last update on September 3, 2024, replacing the estimated last update from September 2, 2024.SummaryDifference0.1%
- Check34 days agoChange DetectedA new Phase II study has been added focusing on the combination of Pembrolizumab, Letrozole, and Palbociclib for treating postmenopausal patients with newly diagnosed metastatic Stage IV estrogen receptor-positive breast cancer, while a previous study with similar focus has been removed.SummaryDifference14%
- Check55 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab & Endocrine Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Endocrine Therapy Clinical Trial page.